GLA
XERS icon

Great Lakes Advisors’s Xeris Biopharma Holdings XERS Stock Holding History

Great Lakes Advisors’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-34,841
Closed -$142K – 743
2021
Q2 		$142K Buy
+34,841
New +$133K ﹤0.01% 682

Other funds holding XERS

SC
Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Great Lakes Advisors's XERS Position: Q3 2021 in Review

Great Lakes Advisors sold out of Xeris Biopharma Holdings (XERS) in Q3 2021, closing a stake of 34,841 shares — an estimated $142K sold.

Great Lakes Advisors first reported a position in XERS in Q2 2021 and held it in 1 quarter. The position peaked at $142K in Q2 2021. 70 funds tracked by Wall St. Rank hold XERS as of Q3 2021.

  • Great Lakes Advisors reported no remaining Xeris Biopharma Holdings position as of Q3 2021 after selling out during the quarter.
  • Great Lakes Advisors sold 34,841 Xeris Biopharma Holdings shares in Q3 2021, an estimated $142K.
  • Great Lakes Advisors first reported a position in Xeris Biopharma Holdings in Q2 2021 and held it in 1 quarter.
  • Great Lakes Advisors's Xeris Biopharma Holdings position peaked at $142K in Q2 2021.
  • 70 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q3 2021.

Based on Great Lakes Advisors's 13F filing for Q3 2021, filed 9 Nov 2021.